ArticleClinical case reports2026
SCORTEN in Contrast: Two Cases of SJS/TEN Overlap With Divergent Outcomes Highlighting the Role of Renal Dysfunction.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap is a rare, life-threatening mucocutaneous reaction typically induced by medications. Reports from Central America remain scarce. We present two contrasting cases of SJS/TEN overlap from Nicaragua. Case 1 involved a previously healthy 18-year-old male who developed SJS/TEN overlap with 20% total body surface area (TBSA) involvement following exposure to amoxicillin, diclofenac, and levofloxacin. His SCORTEN score was 1 (estimated mortality < 10%). He received systemic corticosteroids and achieved complete recovery with no sequelae. Case 2 involved a 32-year-old female with stage G5 chronic kidney disease (CKD) not on dialysis who developed SJS/TEN overlap with 30% TBSA involvement after metamizole and acetaminophen exposure. Her SCORTEN score was 2 (estimated mortality ~12%). Despite initial cutaneous improvement with corticosteroids, she developed progressive uremia, refused renal replacement therapy, and ultimately died from multiorgan failure on day 28. These cases illustrate that SCORTEN may have limited ability to capture late mortality driven by pre-existing renal dysfunction and systemic complications. Furthermore, they suggest that cutaneous improvement with corticosteroids does not necessarily translate into survival when underlying organ vulnerability exists. Individualized clinical assessment beyond prognostic scores remains essential, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.